Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Britain Courts Anthropic Amid US Defense Department Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
PLANO, Texas, March 01, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Wednesday, March 8, 2017
Time: 8:40 am ET
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
